임상시험 트래커

추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov

8건 표시

• 임상
  3상모집 중· Relapsed or Refractory Large B-cell Lymphoma

  Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

  협력: 길리어드

  상세 →NCT07479797
• 임상
  3상모집 중· Extensive Stage Small Cell Lung Cancer (ES-SCLC)

  Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

  리드: 길리어드

  상세 →NCT06801834
• 임상
  3상모집 중· Disseminated Histoplasma Capsulatum Infection

  Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS

  협력: 길리어드

  상세 →NCT05814432
• 임상
  3상모집 중· Triple Negative Breast Cancer

  NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)

  협력: 길리어드, 머크(MSD)

  상세 →NCT06081244
• 임상
  3상모집 중· HIV/AIDS

  Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France.

  협력: 길리어드

  상세 →NCT05813964
• 임상
  3상모집 중· Triple Negative Breast Cancer

  Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer

  협력: 길리어드

  상세 →NCT05552001
• 임상
  3상모집 중· Primary Biliary Cholangitis

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  리드: 길리어드

  상세 →NCT06051617
• 임상
  3상모집 중· Triple Negative Breast Cancer

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  리드: 길리어드

  상세 →NCT05633654

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.